Strathmore Plus Uranium Corp (SUU) NPV

Sell:0.12 CADBuy:0.13 CADNo change

Prices delayed by at least 15 minutes
Sell:0.12 CAD
Buy:0.13 CAD
Change:No change
Prices delayed by at least 15 minutes
Sell:0.12 CAD
Buy:0.13 CAD
Change:No change
Prices delayed by at least 15 minutes

Company Information

About this company

Strathmore Plus Uranium Corp. is a Canada-based exploration stage company. The Company is focused on discovering uranium deposits in Wyoming, The Company acquires, explores and develops resource properties in Wyoming, the United States of America. The Company has three uranium projects in Wyoming, including Night Owl, Agate, and Beaver Rim. The Night Owl project is located in the Shirley Basin Uranium District, east-central Wyoming. The project consists of over 82 unpatented lode mining claims covering approximately 666 hectares and one State of Wyoming mineral lease covering over 266 hectares. The Agate property consists of approximately 67unpatented lode mining claims covering 1,384 acres. The Beaver Rim project is located in the Gas Hills Uranium District, Central Wyoming. The project consists of approximately 131 lode mining claims totaling 1,095 acres.

Key people

Devinder Randhawa
Chairman of the Board, President, Chief Executive Officer
Ryan Cheung
Chief Financial Officer
Terrence Osier
Vice President of Exploration
Marion Edgar Edgar Loomis
Director
John Dejoia
Independent Director
Jordan Potts
Independent Director
Click to see more

Key facts

  • EPIC
    SUU
  • Location
    Canada
  • Sector
    Basic Materials
  • Industry
    Metal Mining
  • ISIN
    CA86308P1027
  • Market cap
    CA$5.83m
  • Employees
    -
  • Shares in issue
    48.91m
  • Exchange
    TSX Venture Exchange
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.